Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Prof Kenneth Cusi, USA, discusses the role of insulin sensitizers in NASH, and particularly how lifestyle interventions including weight loss can, in this context, be beneficial together with a pharmacological approach.
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Prof Manal Abdelmalek, USA highlights the role that PPAR agonists could play in the treatment of NASH. This video was filmed in Boston during the Liver meeting 2019.
Prof Gracia-Sancho, Spain, discusses his oral presentation at the Liver meeting 2019 in Boston and the reasons why PPAR agonists could be a very valuable therapeutic option for the treatment of advanced chronic liver disease.
Prof Gyongyi Szabo, USA discusses the role of PPARs in NASH fibrogenesis. This video was filmed in Boston during the Liver meeting 2019.
Prof Frank Tacke, Germany, discusses the role of PPARs in adipose tissue and liver inflammation. This video was filmed in Boston during the Liver meeting 2019.
For me, one of the key take home messages of this 2019 Liver Meeting is that we now understand the need to develop therapeutic approaches that target more than one molecular pathway of the disease. Chronic liver disease is multifactorial…